

2016 Gastroenterology Preferred Specialty Measure Set

PQRS#	NQF#	Reporting Method	National Quality Strategy Domain	Measure Title: Description
113	0034	Registry, Claims, EHR, GPRO (Web Interface), Measures Groups	Effective Clinical Care	Colorectal Cancer Screening: Percentage of patients 50 through 75 years of age who had appropriate screening for colorectal cancer
185	0659	Claims, Registry	Communication and Care Coordination	Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use: Percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior adenomatous polyp(s) in previous colonoscopy findings, who had an interval of 3 or more years since their last colonoscopy
226	0028	Claims, Registry, EHR, GPRO (Web Interface), Measures Groups	Community/ Population Health	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention: Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user
320	0658	Claims, Registry	Communication and Care Coordination	Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients: Percentage of patients aged 50 to 75 years of age receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report
343	N/A	Registry	Effective Clinical Care	Screening Colonoscopy Adenoma Detection Rate: The percentage of patients age 50 years or older with at least one conventional adenoma or colorectal cancer detected during screening colonoscopy
387	N/A	Registry	Effective Clinical Care	Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users: Percentage of patients regardless of age who are active injection drug users who received screening for HCV infection within the 12 month reporting period
390	N/A	Registry, Measures Groups	Person and Caregiver-Centered Experience and Outcomes	Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options: Percentage of patients aged 18 years and older with a diagnosis of hepatitis C with whom a physician or other qualified healthcare professional reviewed the range of treatment options appropriate to their genotype and demonstrated a shared decision making approach with the patient. To meet the measure, there must be documentation in the patient record of a discussion between the physician or other qualified healthcare professional and the patient that includes all of the following: <ul style="list-style-type: none"> •Treatment choices appropriate to genotype •Risks and benefits •Evidence of effectiveness •Patient preferences toward treatment
400	N/A	Registry	Effective Clinical Care	One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk: Percentage of patients aged 18 years and older with one or more of the following: a history of injection drug use, receipt of a blood transfusion prior to 1992, receiving maintenance hemodialysis OR birthdate in the years 1945-1965 who received a one-time screening for HCV infection

2016 Gastroenterology Preferred Specialty Measure Set

PQRS#	NQF#	Reporting Method	National Quality Strategy Domain	Measure Title: Description
401	N/A	Registry, Measures Groups	Effective Clinical Care	Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in patients with Cirrhosis: Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who were screened with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month reporting period
438	N/A	Registry, GPRO (Web Interface), Measures Groups	Effective Clinical Care	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease: Percentage of the following patients—all considered at high risk of cardiovascular events—who were prescribed or were on statin therapy during the measurement period: <ul style="list-style-type: none"> • Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR • Adults aged ≥ 21 years with a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL; OR • Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL
439	N/A	Registry	Efficiency and Cost Reduction	Age Appropriate Screening Colonoscopy: The percentage of patients greater than 85 years of age who received a screening colonoscopy from January 1 to December 31

This table is a resource of potential measures that may be applicable to eligible professionals providing clinical services for Gastroenterology. Please note that in addition to this table, a cross cutting measures list is also available for reporting at the following link: [2016 Cross-Cutting Measures List](#)